Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group’s expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. The Company was originally formed in 2000 and this year celebrates its 10 year anniversary.
The Biomarker division provides services to drug development companies using its cDNA amplification technology and expertise in gene expression analysis. In addition to the service offering, Epistem has recently marketed RNA-Amp kits, a new generation of amplification kits which enable researcher’s to perform amplification from small amounts of starting materials. The Company also offers publically available or proprietary biomarker panels to well known disease pathways that could be used to measure drug-induced gene expression change during treatment.